Analyst Ratings For BioMarin Pharmaceutical (NASDAQ:BMRN)
Today, Credit Suisse Group raised its price target on BioMarin Pharmaceutical (NASDAQ:BMRN) to $116.00 per share.
Some recent analyst ratings include
- 2/27/2018-Royal Bank of Canada Reiterated Rating of Hold.
- 2/25/2018-JPMorgan Chase & Co. Reiterated Rating of Buy.
- 2/23/2018-BMO Capital Markets Reiterated Rating of Outperform .
Recent Insider Trading Activity For BioMarin Pharmaceutical (NASDAQ:BMRN)
BioMarin Pharmaceutical (NASDAQ:BMRN) has insider ownership of 1.85% and institutional ownership of 98.77%.
- On 2/15/2018 Jean Jacques Bienaime, CEO, sold 10,000 with an average share price of $84.63 per share and the total transaction amounting to $846,300.00.
- On 2/1/2018 George Eric Davis, EVP, sold 30,000 with an average share price of $90.66 per share and the total transaction amounting to $2,719,800.00.
- On 1/5/2018 Jean Jacques Bienaime, CEO, sold 10,000 with an average share price of $90.32 per share and the total transaction amounting to $903,200.00.
- On 1/2/2018 Henry J. Fuchs, Insider, sold 15,000 with an average share price of $89.23 per share and the total transaction amounting to $1,338,450.00.
- On 1/2/2018 V Bryan Lawlis, Director, sold 3,750 with an average share price of $88.84 per share and the total transaction amounting to $333,150.00.
- On 12/29/2017 Jean Jacques Bienaime, CEO, sold 20,000 with an average share price of $89.75 per share and the total transaction amounting to $1,795,000.00.
- On 12/29/2017 Jean Jacques Bienaime, CEO, sold 10,000 with an average share price of $89.61 per share and the total transaction amounting to $896,100.00.
Recent Trading Activity for BioMarin Pharmaceutical (NASDAQ:BMRN)
Shares of BioMarin Pharmaceutical closed the previous trading session at 78.18 up +0.51 0.66% with 79.1500015258789 shares trading hands.